CStone Pharmaceuticals grants share options and RSUs to key personnel

CStone Pharmaceuticals granted a total of 4.8m share options and 1.93m restricted share units (RSUs) on August 27, 2025, to five grantees, including one director and four employees. The share options have an exercise price of HK$10.00 per share, determined by the higher of the closing price on the grant date and the average closing price for the five preceding business days. The RSUs were granted at a closing price of HK$10.00 per share.

Among the grants, Jianxin Yang, chief executive officer and executive director, received 2.4m share options and 330,000 RSUs. Vesting periods vary, with a significant portion set to commence on August 27, 2025, and some on August 4, 2025, with specific percentages vesting annually or monthly over several years. Both share options and RSUs are subject to annual performance targets and clawback mechanisms for reasons such as misconduct or fraud.

Following these grants, 44,861,835 underlying shares remain available for future grants under the scheme mandate limit, and 12,663,640 underlying shares are available under the service provider sublimit. The board views these grants as fair and reasonable, aligning participant interests with shareholder value and serving to attract and retain talent.